JPMorgan Chase & Co. Makes New $3.68 Million Investment in Niagen Bioscience, Inc. $NAGE

JPMorgan Chase & Co. bought a new position in shares of Niagen Bioscience, Inc. (NASDAQ:NAGE) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 394,166 shares of the company’s stock, valued at approximately $3,678,000. JPMorgan Chase & Co. owned 0.49% of Niagen Bioscience as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Financial Consulate Inc. purchased a new stake in Niagen Bioscience in the third quarter worth $33,000. Ameritas Investment Partners Inc. purchased a new stake in shares of Niagen Bioscience in the 3rd quarter worth about $45,000. State of Alaska Department of Revenue bought a new position in shares of Niagen Bioscience in the 3rd quarter worth about $44,000. North Star Investment Management Corp. purchased a new position in Niagen Bioscience during the 3rd quarter valued at about $47,000. Finally, Quantbot Technologies LP bought a new stake in Niagen Bioscience during the third quarter worth about $48,000. Hedge funds and other institutional investors own 15.41% of the company’s stock.

Niagen Bioscience Price Performance

Shares of NAGE opened at $4.38 on Friday. Niagen Bioscience, Inc. has a twelve month low of $4.16 and a twelve month high of $14.69. The company has a market capitalization of $350.75 million, a P/E ratio of 21.90 and a beta of 2.23. The firm has a 50 day moving average of $5.05 and a 200 day moving average of $6.43.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on NAGE. Canaccord Genuity Group reaffirmed a “buy” rating and set a $13.00 target price on shares of Niagen Bioscience in a research note on Tuesday. Wall Street Zen upgraded Niagen Bioscience from a “hold” rating to a “buy” rating in a research note on Saturday, March 28th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Niagen Bioscience in a research note on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $16.00.

Niagen Bioscience Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.